Aytu Biopharma Inc is a biopharmaceutical company focused on developing and commercializing innovative healthcare solutions, particularly in the fields of urology and endocrinology. The company aims to address unmet medical needs through its diverse portfolio of products and therapeutic options. Aytu leverages its expertise in research and development to bring forward new treatments that enhance patient outcomes and improve quality of life. Through strategic partnerships and a commitment to advancing science, the company seeks to deliver impactful therapies that drive meaningful change in the healthcare landscape. Read More
NEW YORK, NY / ACCESS Newswire / September 25, 2025 / The MicroCap Rodeo Conference is live today, featuring presentations from the CEOs and executive management teams of 11 dynamic microcap companies across a wide range of industries.
DENVER, CO / ACCESS Newswire / September 24, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced management will participate at the following investor conferences:
Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session.
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Aytu BioPharma shares fell after Q4 2025 results missed revenue and EPS estimates. The company remains focused on the upcoming launch of its depression drug, EXXUA, as a key growth catalyst.
NEW YORK, NY – September 23, 2025 – As the trading day concludes, all eyes in the biopharmaceutical sector are turning to Aytu BioPharma (NASDAQ: AYTU), which is poised to release its fiscal fourth-quarter and full-year 2025 operational and financial results after market close today. Investors and analysts are keenly awaiting these
DENVER, CO / ACCESS Newswire / September 16, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its fiscal 2025 full year and fourth quarter, after the market close on Tuesday, September 23, 2025. The Company has scheduled a conference call and webcast that same day, Tuesday, September 23, 2025, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.
DENVER, CO / ACCESS Newswire / June 25, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced the appointment of Dr. Gerwin Westfield, PhD as Senior Vice President of Scientific Affairs, effective June 30, 2025. In his role, Dr. Westfield will oversee the Company's medical and scientific affairs strategies, with a primary focus on the upcoming commercial launch of EXXUA™ (gepirone) extended-release tablets ("EXXUA"), a novel, branded, United States Food and Drug Administration ("FDA") approved treatment for major depressive disorder ("MDD") in adults in the United States.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session.
Aytu enters the over $22 billion United States prescription major depressive disorder ("MDD") market with the first-in-class oral selective serotonin 5HT1a receptor agonist for adults with MDD.
